NCT00987948

Maraviroc Intensification and Peripheral Blood Monocyte HIV DNA Levels

Pilot Study of the Effect of Maraviroc Intensification on Peripheral Blood Monocyte HIV DNA Levels When Given to HIV-Infected Subjects Stable on Highly Active Antiretroviral Therapy With Undetectable Plasma HIV RNA

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 15 (actual)
• Sponsor: University of Hawaii · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

High levels of HIV infection within blood monocyte/macrophages (a type of white cells in the bloodstream) increases risk of dementia in HIV-infected individuals. Maraviroc (Selzentry) is a HIV medication that works by blocking the entry of HIV in cells including monocytes/macrophages that use a receptor called CCR5. The study hypothesis is that the addition of Maraviroc to a HIV antiretroviral regimen in HIV-infected individuals with high levels of HIV-infected monocyte/macrophages will lead to a decrease in the levels of infected monocyte/macrophages and to decrease in brain inflammation as studied by magnetic resonance spectroscopy (MRS, a form of MRI study).

Conditions

• HIV Infections

Interventions

Type	Name	Description
DRUG	maraviroc (Selzentry)	dosage varies with other medications being taken; will follow package insert guidelines

Timeline

• Start date: 2010-01-01
• Primary completion: 2012-11-01
• Completion: 2013-08-01
• First posted: 2009-10-01
• Last updated: 2017-03-22
• Results posted: 2017-03-22

Locations

1 site across 1 country: United States